Trial Profile
A Single-center, Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending 14-day Repeated Oral Doses of Genz-682452 in Healthy Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs Genz 682452 (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- Sponsors Sanofi
- 09 Apr 2014 New trial record